As of November 6, 2026, Rapport Therapeutics, Inc. is a publicly traded company (Nasdaq: RAPP); its largest reported holder is Third Rock Ventures V, L.P., with 13.1% on Schedule 13G/A of August 14, 2026, then Capital International Investors (6.1%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Rapport Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Rapport Therapeutics, Inc. a real, registered company?
- Rapport Therapeutics, Inc. files with the SEC under CIK 2012593 (its SEC filings).
- Its shares are listed under the ticker RAPP on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Rapport Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Cormorant Asset Management, LP (filed 2026-08-14).
Who are Rapport Therapeutics, Inc.'s owners and officers?
Rapport Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Cormorant Asset Management, LP | 5.56% |
| Schedule 13G/A, 2026-08-14 | Third Rock Ventures V, L.P. | 13.1% |
| Schedule 13G/A, 2026-08-12 | Capital International Investors | 6.1% |
| Schedule 13G/A, 2026-05-15 | Cormorant Asset Management, LP | 6.19% |
| Schedule 13G/A, 2026-02-17 | Cormorant Asset Management, LP | 6.35% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.03% |
| Schedule 13G/A, 2025-11-14 | Cormorant Asset Management, LP | 6.7% |
| Schedule 13G/A, 2025-10-22 | Johnson & Johnson | 4.9% |
| Schedule 13D/A, 2025-09-18 | Sofinnova Venture Partners Xi, L.P. ("Svp Xi") | 4.2% |
Questions about who owns Rapport Therapeutics, Inc.
Who owns Rapport Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Rapport Therapeutics, Inc.: Third Rock Ventures V, L.P. (13.1%, Schedule 13G/A, filed 2026-08-14), Capital International Investors (6.1%, Schedule 13G/A, filed 2026-08-12), Cormorant Asset Management, LP (5.56%, Schedule 13G/A, filed 2026-08-14) and Blackrock, Inc. (5.03%, Schedule 13G, filed 2026-01-21).
Who are the largest shareholders of Rapport Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Rapport Therapeutics, Inc. on this page are Third Rock Ventures V, L.P. (13.1%), Capital International Investors (6.1%) and Cormorant Asset Management, LP (5.56%).
When did Third Rock Ventures V, L.P. buy into Rapport Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Third Rock Ventures V, L.P. on this page is the Schedule 13G/A, filed 2026-08-14, reporting 13.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Rapport Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Rapport Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rapport Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Rapport Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Third Rock Ventures VI, L.P., a director and 10% owner: 8,678,314 shares (14.6% of shares outstanding), 6,518,620 held directly and 2,159,694 indirectly, on a joint filing (Form 4, 2026-11-03).
- TRV GP V, LLC, a director and 10% owner: 8,678,314 shares (14.6% of shares outstanding), 6,518,620 held directly and 2,159,694 indirectly, on a joint filing (Form 4, 2026-11-03).
- Third Rock Ventures GP V, LP, a director and 10% owner: 8,678,314 shares (14.6% of shares outstanding), 6,518,620 held directly and 2,159,694 indirectly, on a joint filing (Form 4, 2026-11-03).
- Third Rock Ventures V, L.P., a director and 10% owner: 8,678,314 shares (14.6% of shares outstanding), 6,518,620 held directly and 2,159,694 indirectly, on a joint filing (Form 4, 2026-11-03).
- Third Rock Ventures GP VI, L.P., a director and 10% owner: 8,678,314 shares (14.6% of shares outstanding), 6,518,620 held directly and 2,159,694 indirectly, on a joint filing (Form 4, 2026-11-03).
Shares outstanding: 59,279,630 as of 2026-11-02, from the company's latest SEC cover page.
How much has Rapport Therapeutics, Inc. raised?
No fundraising or offering filing from Rapport Therapeutics, Inc. is on file with us.
Keep reading
More on Rapport Therapeutics, Inc. and the records around it.
Rapport Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- JOHNSON & JOHNSON also filed stake reports on 2 other companies: Rallybio Corporation (Apr 2026), CVRx, Inc. (Jan 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/rapport-therapeutics